(Pseudo)amide-linked oligosaccharide mimetics: molecular recognition and supramolecular properties

Page 1 of (page number not for citation purposes) 18 (Pseudo)amide-linked oligosaccharide mimetics: molecular recognition and supramolecular properties José L. Jiménez Blanco*1, Fernando Ortega-Caballero1, Carmen Ortiz Mellet1 and José M. García Fernández2 Review Open Access Address: 1Department of Organic Chemistry, Faculty of Chemistry, University of Seville, Prof. García González 1, Seville 41012, Spain and 2Institute of Chemistry Research, CSIC-University of Seville, Americo Vespucio 49, Seville 41092, Spain Email: José L. Jiménez Blanco* - [email protected] * Corresponding author Keywords: carbopeptoids; glycoclusters; glycomimetics; pseudooligosaccharides; spaced sugars Beilstein Journal of Organic Chemistry 2010, 6, No. 20. doi:10.3762/bjoc.6.20 Received: 01 December 2009 Accepted: 11 February 2010 Published: 22 February 2010 Guest Editor: T. K. Lindhorst © 2010 Jiménez Blanco et al; licensee Beilstein-Institut. License and terms: see end of document. Abstract Oligosaccharides are currently recognised as having functions that influence the entire spectrum of cell activities. However, a distinct disadvantage of naturally occurring oligosaccharides is their metabolic instability in biological systems. Therefore, much effort has been spent in the past two decades on the development of feasible routes to carbohydrate mimetics which can compete with their O-glycosidic counterparts in cell surface adhesion, inhibit carbohydrate processing enzymes, and interfere in the biosynthesis of specific cell surface carbohydrates. Such oligosaccharide mimetics are potential therapeutic agents against HIV and other infections, against cancer, diabetes and other metabolic diseases. An efficient strategy to access this type of compounds is the replacement of the glycosidic linkage by amide or pseudoamide functions such as thiourea, urea and guanidine. In this review we summarise the advances over the last decade in the synthesis of oligosaccharide mimetics that possess amide and pseudoamide linkages, as well as studies focussing on their supramolecular and recognition properties. Page 1 of (page number not for citation purposes) 18 Review Among the major classes of biomolecules, carbohydrates are characterized by nearly unlimited structural diversity. Monosaccharide units can combine to produce oligosaccharides in a number of permutations that increases rapidly with the number of units present, more so than is the case with other biomolecules such as polypeptides or oligonucleotides. This is determined by the stereochemical identity of the monosaccharide units present (e.g. glucose, galactose, mannose), their glycosidic linkage positions (e.g. 1→4, 1→6), the nature at anomeric centres (α or β), the presence of additional substituents such as sulfate or acyl groups and the overall degree of branching. The molecular diversity of oligosaccharide offers a valuable tool for drug discovery in the areas of biologically important oligosaccharides, glycoconjugates and molecular scaffolds by investigating their structural and functional impact. Currently, oligosaccharides are known to have functions in a Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 2 of (page number not for citation purposes) 18 Figure 1: Schematic representation of sugar aminoacids (SAAs) and (pseudo)amide oligosaccharide mimetics. broad variety of cell–cell interactions related to invading bacteria, viruses and cancer cells [1-4] and to play central roles in post-translational modifications of proteins [5-7], cell–cell communication [8] and immune response to pathogens [7,9-11]. However, the application of oligosaccharides as potential therapeutic agents has its main drawback in the low instability of natural carbohydrates in biological systems. In addition, solid phase synthesis of oligosaccharides is not yet efficient enough for generating oligosaccharide-based libraries that may be useful in the future for the discovery of new therapeutic drugs. Taking into account the increasing importance of glycobiology and the difficulties associated to the synthesis of carbohydratebased libraries, several approaches based on the assembly of sugar building blocks through amide and pseudoamide linkages have been developed by different research groups over the last few years. Sugar aminoacids (SAAs, Figure 1) have extensively been used in the development of a large variety of molecules. In the past 10 years, some reviews on SAAs have summarised the different synthetic methods used to obtain such molecules [12-14] as well as their applications to access to a diversity of linear, branched and cyclic pseudooligosaccharides and glycomimetics often referred to as carbopeptoids [13-17]. In addition, SAAs have been widely used in the field of material sciences as carbohydrate-derived monomers for the design of novel chiral polyamides [18]. Nevertheless, these review articles mainly focus on amide-linked sugars and do not pay too much attention to other types of pseudosugars. A notable exception is the contribution by Wessel and Dias Lucas, who recently published an interesting review where oligosaccharide mimetics which deviate from the natural linking pattern were discussed [19]. This review also included pseudoamide-linked sugars (Figure 1). In this current review we have tried to highlight the recent advances in the synthesis of oligosaccharide mimetics. We have focussed on amide and pseudoamide-linked oligosaccharides, and their molecular recognition properties. We intend this survey to be wide-ranging and cover the most recent trends in the field. Amide-linked sugars: carbopeptoids The replacement of the glycosidic oxygen atom by an amide group leads to amide-linked sugars (Figure 1), which are synthesised by the sequential coupling of SAAs to form a class of compounds commonly referred to as carbopeptoids. The use of the amide functional group to connect sugar building blocks is inspired by the structure of peptides and the potential of carbohydrates to reproduce the structural features and biological properties of these polymers [12,13,17]. Poor bioavailability and metabolic stability of peptides have resulted in significant limitations as drug candidates. Another general problem is the loss of the original conformation in the isolated peptide fragments present in natural proteins, where the rest of molecule fixes a specific spatial disposition. Furthermore, short linear peptides cannot be restricted to adopt a particular conformation that enables effective interaction with a receptor [20]. As a consequence, a wide variety of methods to restrict the conformational freedom has been developed. One approach to get round this problem is the isosteric replacement of the amide bond in the peptide with a suitable mimetic to induce a specific secondary structure. Recent investigations have demonstrated that incorporation of SAAs in peptide structures can circumvent the adverse properties of bioactive natural systems. Thus, SAAs containing amino and carboxylic functional groups, and a rigid ring system (pyran, furan, oxetane) have emerged as versatile and conformationally constrained building blocks for the formation of peptide and oligosaccharide mimetics using standard peptide coupling techniques in solution or in the solid phase. Exploitation of the rigidity and diversity of the sugar backbone should permit subtle modifications and the rational design of oligomeric derivatives with tendency to adopt specific compact conformations (foldamers). Linear naturally-occurring SAA homooligomers SAAs occur extensively in nature as subunits of oligosaccharides in cell walls such as N-acetylneuraminic 1 and muramic acids 2, as well as in some nucleoside antibiotics (e.g., gougerotin 3 and aspiculamycin 4) (Figure 2). Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 3 of (page number not for citation purposes) 18 Figure 2: Natural SAAs structures and natural nucleosidic antibiotics. Scheme 1: Synthetic route to the target amide-linked sialooligomers. (a) Fmoc-Cl, NaHCO3, H2O, dioxane, 0 °C. (b) Ac2O, Pyridine, 0 °C. (c) BOP, DIPEA. (d) NH2NH2·H2O, MeOH. N-Acetylneuraminic acid is a readily available naturally occurring δ amino acid. By applying solid phase peptide methods on Rink resin with Fmoc protecting group chemistry [21,22], Gervay and co-workers have reported a series of (1→5) amidelinked sialooligomers ranging from dimeric to octameric species (Scheme 1) [23,24]. All of these were soluble in water, DMSO and methanol, which allowed NH/ND exchange NMR experiments and circular dichroism (CD) studies to be carried out. Combined structural studies showed that a tetramer is required for an ordered secondary structure [23,25]. Linear non-naturally-occurring SAA homooligomers The first examples of amide-linked SAA-pyranose oligomers were reported as long ago as 1975 by Fuchs and Lehman [26,27]. In 2002, Ichikawa and co-workers developed a synthetic methodology to access oligomers of glycoamino acids, a family of non-natural SAAs with a carboxyl group at C-1 position and an amino group replacing one of the hydroxyl groups at either the C-2, 3, 4 or 6 positions (Figure 3). Glucose-type building blocks were prepared and used to construct β(1→2), β(1→3), β(1→4) and β(1→6)-linked homooligomers [28-30] that were found to form rigid secondary structures predetermined by the linkage position as evidenced from CD and NMR measurements. Moreover, conformational analysis by molecular modelling calculation on the β(1→2)- linked decamer 9 supported a helical arrangement, stabilised by a intramolecular hydrogen bonding in the form of a 16-membered ring, characteristic for β-peptides (Figure 4) [29]. Analogously, NMR and IR data of a β(1→6)-linked unsaturated glycamino acid tetramer showed a turn-like structure in chloroform solution [31]. Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 4 of (page number not for citation purposes) 18 Figure 3: The general structure of glycoamino acids and their corresponding oligomers. Figure 4: Conformational analysis of the β(1→2)-amide-linked glucooligomer 9. Figure 5: Short oligomeric chains of C-glycosyl D-arabino THF amino acid oligomers. Glycoamino acid-based carbopeptoids are resistant to glycosidases and exhibit interesting biological activities. Thus, the O-sulfated β(1→2) and β(1→6)-linked homo-oligomers effectively inhibit L-selectin-mediated cell adhesion, HIV infection and heparanase acitivity in a linkage-specific manner [28]. SAAs can have a wide range of structural diversity as a consequence of differing on ring sizes, structural manipulation (such as chain branching, deoxygenation, hydroxyl protection, unsaturation), relative position between amine and carboxylic function, and, perhaps most importantly, the spatial arrangement of the amine and acid moieties. The limitations of stereocontrol of glycosidic linkages can be circumvented by their replacement by an amide function. Furthermore, as a result of the presence of amine and acid moieties, SAAs are suitable for conventional combinatorial synthesis in both solid and solution phase. Many of these aspects have been extensively studied by Fleet’s group over the last 10 years. Efficient synthetic procedures for protected and unprotected homo-oligomeric derivatives of D-arabino- (Figure 5) [32-34] , D-talo- [35], L-allo- [35], D-galacto- [36], D-allo- [37], D-lyxo- [38], L-xylo- [39] and L-ribo-configured [39] tetrahydrofuran (THF) amino acids were optimised in order to study the influence of ring configuration and protecting groups on the secondary structure in these carbopeptoids. Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 5 of (page number not for citation purposes) 18 Figure 6: (A) Stereoview of the minimized structure of compound 16 (produced by a 500 ps simulation) that most satisfies the 27 NOE derived distance constraints. (B) View looking from C to N terminus. Hydrogen bonds are indicated by dotted lines. Short oligomeric chains of C-glycosyl β-D-arabino THF amino acids 14 and 15 (where the C-2 and C-5 substituents of the THF ring are cis to each other) exhibit a well defined repeating turn secondary structure stabilised by inter-residual hydrogen bonds, whereas the epimeric α-D-arabinofuranose oligomer 12 (with the C-2 and C-5 substituents in trans relative disposition) do not show any secondary structure in solution [34]. NMR and IR studies on D-galacto- [36] and D-allo-configured [37] oligomeric carbopeptoids demonstrated that the inversion of a single stereocentre on the THF ring can have more pronounced effects for solution conformations than the presence or absence of different protecting groups. Thus, 2,4-cis-THF-L-ribonate oligomers adopt hydrogen bond stabilised conformations whereas 2,4-trans-THF-L-xylonate oligomers do not. Additionally, a number of structurally related THF aminoacid oligomers were examined by chiroptical spectroscopy to aid interpretation of their conformational preferences. The use of CD, in addition to NMR and solution IR, enabled the classification of the conformations adopted by carbopeptoids as hydrogen bonded regular, non-hydrogen bonded regular and non-hydrogen bonded irregular [40]. “Regular” is used to define a conformation that is either hydrogen bonded or non-hydrogen bonded and not in equilibrium with other multiple conformations. If conformational exchange operates, the term “irregular” is used. For example, these studies demonstrated that an octameric chain of C-glycosyl α-D-lyxo furanose amino acids 16 adopts a regular hydrogen bonded conformation similar to an π-helix (Figure 6) [38], whereas α-D-lyxo [38], D-talo and L-lyxo tetramers have regular non-hydrogen bonded conformations [40]. Also, based on these techniques, Andreini et al. [41] have recently demonstrated that homo-oligomers of β-SAA (β-N- mannofuranosyl-3-ulosonic acid) adopt eight-membered ring hydrogen bonded double-turn regular conformations in solution. Chakraborty’s group has also prepared protected and unprotected homo-oligomeric derivatives of D-manno- [42] and D-gluco-configured [43] tetrahydrofuran (THF) amino acids and studied their conformational properties by chiroptical and NMR techniques. Although both hydroxyl-protected linear oligomers displayed well-defined turn structures, their unprotected counterparts resulted in a less robust and regular conformation. However, in some cases the studies of the conformational preference in carbopeptoids is quite challenging and must be argued by computational methods [38,44] and infrared iondip spectroscopy [45] in order to interpret the data from CD, IR and NMR experiments reliably. To complement its research programme on foldamer design and because of the absence of structural investigations on linear homo-oligomers constrained by 4-membered rings, Fleet and co-workers undertook the synthesis of carbopeptoids based on the oxetane template (Figure 7) [46-48]. Conformational analysis was carried out for two oxetane β-SAA hexamers with the 6-deoxy-L-altro and D-arabino configurations by means of detailed NMR and IR studies in combination with molecular mechanics [49]. These studies identified a left-handed helical secondary structure for the 6-deoxy-L-altro-oxetane hexamer and a right-handed helical structure for the D-arabino- configured oxetane hexamer 21 (having the opposite absolute configuration at C-2 and C-3) stabilised in both instances by 10-membered ring hydrogen bond arrangement (Figure 8). Similar conformational studies combined with CD spectroscopy have been carried out for homo-oligomers of silylprotected δ-2,4-trans-oxetane-SAAs with different configurations. The results showed that 6-deoxy-L-altronate, D-fuconate and 6-deoxy-D-gulonate oligomers are characterised by irregular non-hydrogen bonded conformations whereas L-rham- noate and D-lyxonate oligomers have regular conformations governed by sterical interactions [50]. In contrast to the δ-2,4- trans-oxetane-SAA oligomers, the δ-2,4-cis-oxetane-L-ribonate tetramer and hexamer adopted a repeating β-turn structure [51] Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 6 of (page number not for citation purposes) 18 Figure 7: Structures of linear oxetane-β- and δ-SAA homo-oligomers 19–20. Figure 8: 10-Membered ring H-bonds in compound 21 consistent with NMR and modelling investigations. Figure 9: General structure of carbopeptoid-oligonucleotide conjugates. dictated by internal 10-membered hydrogen bonded rings. Such conformations are similar to those reported for the δ-2,5-cis- oxetane-THF oligomers [37]. D’Onofrio et al. [52] have carried out solid phase synthesis of oligonucleotides conjugated at the 3′ terminus with (1→6)- amide-linked oligosaccharide mimics (Figure 9). The presence of the saccharide unit at the 3′-end of 18-mers significantly enhanced the stability of the oligonucleotides in bovine fetal serum, non-negatively interfering with their ability to form stable duplexes with complementary DNA strands, as evaluated by UV thermal denaturation studies. Orthogonally protected sugar diamino acids (SDA) were first synthesised by Sicherl and Wittmann [53] and used to form linear and branched amide-linked mimetics (Figure 10). Due to the various possibilities with which SDAs can be connected to each other, a high degree of diversity can be Figure 10: Protected derivatives of 2,6-diamino-2,6-dideoxy-β-D-gluc- opyranosyl carboxylic acid 22 and 23. achieved by employing only a small set of different SDAs. Moreover, oligomeric SDAs with unprotected groups represent a novel type of aminoglycoside mimetics with potential recognition properties towards new RNA targets emerging in the post-genome era. Cyclic SAA homo-oligomers A cyclic array of desired ring size and defined secondary structure of alternating carbohydrate moieties and amide groups might conceivably lead to exquisite specificity of recognition and catalysis. One application of this concept is the mimicry of Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 7 of (page number not for citation purposes) 18 Scheme 2: Strategy for solid-phase synthesis of cyclic trimers and tetramers containing pyranoid δ-SAAs. cyclodextrin inclusion complexes. Thus, Kessler and co-workers have reported the synthesis of cyclic oligomers containing glucopyranosyluronic acid by exploiting standard solid and solution phase coupling procedures [54]. These cyclic homo-oligomers of SAAs behave as host molecules that form inclusion complexes with p-nitrophenol and benzoic acid. Following the same objective, Xie’s group prepared orthogonally protected cyclic homo-oligomers with two to four SAA units that can be selectively or fully deprotected to afford macrocycles that can undergo further functionalisation (Figure 11) [55]. Figure 11: Cyclic homo-oligomers containing glucopyranoid-SAAs. Conformational analysis by molecular modelling showed that the unprotected cyclic trimers and tetramers preferred a 4C1 chair conformation with the oxygen atoms of the sugar ring located in the interior of the cavity and the secondary hydroxyl groups outside. This conformation is in agreement with the capacity of these cyclic carbopeptoids to form inclusion complexes with aromatic guest molecules [54] and Cu(II) ion [56]. Additionally, van Well et al. have described a cyclization/ cleavage strategy for solid phase synthesis of cyclic trimers and tetramers containing pyranoid δ-SAAs (Scheme 2) and reported their structural analysis from ROESY data in combination with molecular dynamics calculations [57]. The results showed that the furanoid and the pyranoid SAA trimers adopt well-defined structures, although the trimer composed of pyranoid SAAs is less flexible than its furanoid counterpart. Chakraborty and co-workers have also synthesised cyclic homo-oligomers of mannose- and glucose-derived furanoid SAAs [58] in order to constrain their conformational degrees of freedom and to induce desirable structural elements essential for their biological activities, such as tubular structures for transporting ions or molecules across membranes. Detailed ROESY, temperature coefficient (Δδ/ΔT) measurements of amide protons and constrained MD simulations revealed that all the Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 8 of (page number not for citation purposes) 18 Figure 13: Aminoglycosidic antibiotics of the glycocinnamoylspermidine family. cyclic oligomers had symmetrical structures, although none of the unprotected cyclic oligomers displayed any ability to transport ions across model membranes according to ion flux studies. Cyclic tetramers of L-rhamno- and D-gulo-configured oxetane- SAAs 24 and 25 (Figure 12) have been synthesised by Fleet et al. [59] as mimics of naturally occurring cyclic peptides and cyclodextrins, although no further conformational and recognition studies on these compounds have currently been published. Figure 12: Cyclic tetramers of L-rhamno- and D-gulo-configured oxetane-SAAs. Urea, carbamate and thiourea-linked sugars The replacement of amide groups by pseudoamide (NH–C = X)–Y; X, Y = O, N, S) has been widely used in peptide chemistry to induce well-defined secondary structures. In carbohydrate chemistry, the incorporation of pseudoamide-type intersaccharide linkages has an additional interest because these functional groups are isosteric with phosphodiesther groups occurring in oligoglycosylphosphates and nucleotides. Some examples of natural compounds having saccharide units connected by pseudoamide linkage are known. For example, the family of glycocinnamoylspermidine antibiotics 26–28, whose structures were determined by Ellestad and co-workers [60] by NMR spectroscopy and X-ray diffraction, are characterised by the presence of a glycosylurea linkage (Figure 13). In 2005, Ichikawa and co-workers described the total synthesis of the glycocinnasperemicin D 29, a broad-spectrum antibiotic against Gram-negative organisms, which contains two highly functionalised aminosugars connected by an urea linkage [61]. While exploring the synthesis of this target molecule, this group established a new method for the stereoselective synthesis of novel β-urea-linked pseudooligosaccharides, which involves the reaction of amine-glycosides with Steyemark-type gluco- and galactopyranosyl oxazolidinones [62,63]. Another example of natural disaccharide analogue containing a pseudoamide linkage is trehazolin 33 [64], which possesses a cyclic isourea functionality between the α-D-glucose and aminocyclopentitol rings. Trehazolin is a potent trehalase inhibitor in which an aminocyclopentitol ring replaces the glucopyranosyl cation postulated as an intermediate in the enzymatic hydrolysis of α,α-trehalose. Although several synthetic methodologies had successfully been applied to prepare this inhibitor, Chiara and co-workers have described a novel complementary approach in which the oxazoline ring is generated by SN2 nucleophilic displacement reaction from the β-hydroxyurea 30 via the triflate intermediate 31 (Scheme 3) [65]. A similar methodology was used by the same authors to prepare the trehazolin analogue 37 with an isothiourea group instead of an isourea group, which is also a potent trehalase inhibitor [66,67]. D-Gluco trehazolin analogues have also been synthesised by means of novel methodology based on the coupling of O-unprotected β-D-glucopyranosyl isothiocyanate with different aminosugars followed by treatment with yellow mercury (II) oxide [68]. Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 9 of (page number not for citation purposes) 18 Scheme 3: Synthesis of (thio)trehazoline, via triflate, from β-hydroxy(thio)urea. Figure 14: Approaches to access pseudoamide-type oligosaccharide mimics. Figure 15: Calystegine B2 analogues 38 and 39 with urea-linked disaccharide structure. There are two general strategies to access pseudoamide-type oligosaccharide mimics: i) nucleophilic addition of sugar derivatives to carbohydrate isocyanates, isothiocyanates or isocyanides; and ii) conversion of sugar azides into glycosyl carbodiimides via a tandem Staudinger-aza-Wittig type reaction with triphenylphosphine and an isothiocyanate, followed by the addition of a nucleophile (H2O, H2S, NH3, amines) (Figure 14). Although this second methodology is more straightforward and versatile than the first, only a few examples of pseudooligosaccharides having cyanamide, urea and thiourea-linkages via the Staudinger reaction have been reported [69,70]. In our group, the carbodiimide approach was used to prepare calystegine B2 analogues with the urea-linked disaccharide structure (Figure 15). These compounds, however, did not show inhibitory activities, probably due to the presence of a hydrophilic sugar substituent at the nitrogen atom of the nor-tropane ring [71,72]. Several groups have shown that disaccharide ureas and carbamates with different bridging positions as α/β-anomers are readily accessible by the coupling reaction of aminosugars or sugars, respectively, and glycosyl-isocyanates [73,74] or isocyanides [75]. However, the experimental difficulties in handling isocyanates has led to the preferential use of sugar carbodiimides as key intermediates for the preparation of glycosylureido sugars [76-79]. From the large number of functional groups that can be employed as surrogates for the natural amide and phosphodi- Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 16 of (page number not for citation purposes) 18 11. Pendse, S.; Sayegh, M. H.; Frank, M. H. Curr. Drug Targets 2003, 4, 469–476. doi:10.2174/1389450033490894 12. Risseeuw, M. D. P.; Overhand, M.; Fleet, G. W. J.; Simona, M. I. Tetrahedron: Asymmetry 2007, 18, 2001–2010. doi:10.1016/j.tetasy.2007.08.004 13. Gruner, S. A. W.; Locardi, E.; Lohof, E.; Kessler, H. Chem. Rev. 2002, 102, 491–514. doi:10.1021/cr0004409 14. Franz, A. H.; Gross, P. H.; Samoshin, V. V. ARKIVOC 2008, i, 271–308. 15. Smith, M. D.; Fleet, G. W. J. J. Pept. Sci. 1999, 5, 425–441. doi:10.1002/(SICI)1099-1387(199910)5:10<425::AID-PSC222>3.0.CO ;2-O 16. Chakraborty, T. K.; Srinivasu, P.; Tapadar, S.; Mohan, B. K. Glycoconjugate J. 2005, 22, 83–93. doi:10.1007/s10719-005-0844-x 17. Schweizer, F. Angew. Chem., Int. Ed. 2002, 41, 230–253. doi:10.1002/1521-3773(20020118)41:2<230::AID-ANIE230>3.0.CO;2- L 18. Varela, O.; Orgueira, H. A. Adv. Carbohydr. Chem. Biochem. 2000, 55, 137–174. doi:10.1016/S0065-2318(00)55005-7 19. Wessel, H. P.; Lucas Dias, S. In Glycoscience; Fraser-Reid, B.; Tatsuta, K.; Thiem, J., Eds.; Springer-Verlag: Berlin Heidelberg, Germany, 2008; pp 2079–2112. doi:10.1007/978-3-540-30429-6_52 20. Chakraborty, T. K.; Ghosh, S.; Jayaprakash, S. Curr. Med. Chem. 2002, 9, 421–435. 21. Müller, C.; Kitas, E.; Wessel, H. P. J. Chem. Soc., Chem. Commun. 1995, 2425–2426. doi:10.1039/C39950002425 22. Wessel, H. P.; Mitchell, C. M.; Lobato, C. M.; Schmid, G. Angew. Chem., Int. Ed. Engl. 1996, 34, 2712–2713. doi:10.1002/anie.199527121 23. Szabo, L.; Smith, B. L.; McReynolds, D.; Parrill, A. L.; Morris, E. R.; Gervay, J. J. Org. Chem. 1998, 63, 1074–1078. doi:10.1021/jo971415e 24. Gregar, T. Q.; Gervay-Hague, J. J. Org. Chem. 2004, 69, 1001–1009. doi:10.1021/jo035312+ 25. McReynolds, K. D.; Gervay-Hague, J. Tetrahedron: Asymmetry 2000, 11, 337–362. doi:10.1016/S0957-4166(99)00560-1 26. Fuchs, E.-F.; Lehmann, J. Chem. Ber. 1975, 108, 2254–2260. doi:10.1002/cber.19751080712 27. Fuchs, E.-F.; Lehmann, J. Carbohydr. Res. 1976, 49, 267–273. doi:10.1016/S0008-6215(00)83144-4 28. Suhara, Y.; Yamaguchi, Y.; Collins, B.; Schnaar, R. L.; Yanagishita, M.; Hildreth, J. E. K.; Shimada, I.; Ichikawa, Y. Bioorg. Med. Chem. 2002, 10, 1999–2013. doi:10.1016/S0968-0896(02)00020-2 29. Suhara, Y.; Kurihara, M.; Kittaka, A.; Ichikawa, Y. Tetrahedron 2006, 62, 8207–8217. doi:10.1016/j.tet.2006.05.080 30. Durrat, F.; Xie, J.; Valéry, J.-M. Tetrahedron Lett. 2004, 45, 1477–1479. doi:10.1016/j.tetlet.2003.12.032 31. Chung, Y.-K.; Claridge, T. D. W.; Fleet, G. W. J.; Johnson, S. W.; Jones, J. H.; Lumbard, K. W.; Stalchulski, A. V. J. Pept. Sci. 2004, 10, 1–7. doi:10.1002/psc.488 32. Smith, M. D.; Long, D. D.; Martin, A.; Marquess, D. G.; Claridge, T. D. W.; Fleet, G. W. J. Tetrahedron Lett. 1999, 40, 2191–2194. doi:10.1016/S0040-4039(99)00109-4 33. Claridge, T. D. W.; Long, D. D.; Hungerford, N. L.; Aplin, R. T.; Smith, M. D.; Marquess, D. G.; Fleet, G. W. J. Tetrahedron Lett. 1999, 40, 2199–2202. doi:10.1016/S0040-4039(99)00111-2 34. Smith, M. D.; Claridge, T. D. W.; Sansom, M. S. P.; Fleet, G. W. J. Org. Biomol. Chem. 2003, 1, 3647–3655. doi:10.1039/b307707c 35. Long, D. D.; Hungerford, N. L.; Smith, M. D.; Brittain, D. E. A.; Marquess, D. G.; Claridge, T. D. W.; Fleet, G. W. J. Tetrahedron Lett. 1999, 40, 2195–2198. doi:10.1016/S0040-4039(99)00110-0 36. Brittain, D. E. A.; Watterson, M. P.; Claridge, T. D. W.; Smith, M. D.; Fleet, G. W. J. J. Chem. Soc., Perkin Trans. 1 2000, 3655–3665. doi:10.1039/b002995p 37. Hungerford, N. L.; Claridge, T. D. W.; Watterson, M. P.; Aplin, R. T.; Moreno, A.; Fleet, G. W. J. J. Chem. Soc., Perkin Trans. 1 2000, 3666–3679. doi:10.1039/b002996n 38. Claridge, T. D. W.; Long, D. D.; Baker, C. M.; Odell, B.; Grant, G. H.; Edwards, A. A.; Tranter, G. E.; Fleet, G. W. J.; Smith, M. D. J. Org. Chem. 2005, 70, 2082–2090. doi:10.1021/jo0480040 39. Edwards, A. A.; Sanjayan, G. J.; Hachisu, S.; Tranter, G. E.; Fleet, G. W. J. Tetrahedron 2006, 62, 7718–7725. doi:10.1016/j.tet.2006.05.067 40. Edwards, A. A.; Fleet, G. W. J.; Tranter, G. E. Chirality 2006, 18, 265–272. doi:10.1002/chir.20248 41. Andreini, M.; Taillefumier, C.; Chrétien, F.; Thery, V.; Chapleur, Y. J. Org. Chem. 2009, 74, 7651–7659. doi:10.1021/jo900966b 42. Chakraborty, T. K.; Jayaprakash, S.; Srinivasu, P.; Govardhana Chary, M.; Diwan, P. V.; Nagaraj, R.; Ravi Sankar, A.; Kunwar, A. C. Tetrahedron Lett. 2000, 41, 8167–8171. doi:10.1016/S0040-4039(00)01425-8 43. Chakraborty, T. K.; Srinivasu, P.; Sakunthala Madhavendra, S.; Kiran Kumar, S.; Kunwar, A. C. Tetrahedron Lett. 2004, 45, 3573–3577. doi:10.1016/j.tetlet.2004.03.048 44. Edwards, A. A.; Alexander, B. D.; Fleet, G. W. J.; Tranter, G. E. Chirality 2008, 20, 969–972. doi:10.1002/chir.20538 45. Jockusch, R. A.; Talbot, F. O.; Rogers, P. S.; Simone, M. I.; Fleet, G. W. J.; Simons, J. P. J. Am. Chem. Soc. 2006, 128, 16771–16777. doi:10.1021/ja0607133 46. Barker, S. F.; Angus, D.; Taillefumier, C.; Probert, M. R.; Watkin, D. J.; Watterson, M. P.; Claridge, T. D. W.; Hungerford, N. L.; Fleet, G. W. J. Tetrahedron Lett. 2001, 42, 4247–4250. doi:10.1016/S0040-4039(01)00660-8 47. Johnson, S. W.; Jenkinson, S. F.; Angus, D.; Pérez-Victoria, I.; Claridge, T. D. W.; Fleet, G. W. J.; Jones, J. H. J. Pept. Sci. 2005, 11, 303–318. doi:10.1002/psc.622 48. Lopez-Ortega, B.; Jenkinson, S. F.; Claridge, T. D. W.; Fleet George, W. J. Tetrahedron: Asymmetry 2008, 19, 976–983. doi:10.1016/j.tetasy.2008.03.030 49. Claridge, T. D. W.; Goodman, J. M.; Moreno, A.; Angus, D.; Barker, S. F.; Taillefumier, C.; Watterson, M. P.; Fleet, G. W. J. Tetrahedron Lett. 2001, 42, 4251–4255. doi:10.1016/S0040-4039(01)00661-X 50. Johnson, S. W.; Jenkinson, S. F.; Pérez-Victoria, I.; Edwards, A. A.; Claridge, T. D. W.; Tranter, G. E.; Fleet, G. W. J. J. Pept. Sci. 2005, 11, 517–524. doi:10.1002/psc.658 51. Claridge, T. D. W.; Lopez-Ortega, B.; Jenkinson, S. F.; Fleet, G. W. J. Tetrahedron: Asymmetry 2008, 19, 984–988. doi:10.1016/j.tetasy.2008.03.029 52. D’Onofrio, J.; De Champdoré, M.; De Napoli, L.; Montesarchio, D.; Di Fabio, G. Bioconjugate Chem. 2005, 16, 1299–1309. doi:10.1021/bc0501606 53. Sicherl, F.; Wittmann, V. Angew. Chem., Int. Ed. 2005, 44, 2096–2099. doi:10.1002/anie.200462595 54. Locardi, E.; Stöckle, M.; Gruner, S.; Kessler, H. J. Am. Chem. Soc. 2001, 123, 8189–8196. doi:10.1021/ja010181k 55. Ménand, M.; Blais, J.-C.; Hamon, L.; Valéry, J.-M.; Xie, J. J. Org. Chem. 2005, 70, 4423–4430. doi:10.1021/jo0502899 Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 17 of (page number not for citation purposes) 18 56. Fournier, F.; Afonso, C.; Ménand, M.; Hamon, L.; Xie, J.; Tabeta, J.-C. Eur. J. Mass Spectrom. 2008, 14, 61–69. doi:10.1255/ejms.912 57. van Well, R. M.; Marinelli, L.; Erkelens, K.; van der Marel, G. A.; Lavecchia, A.; Overkleeft, H. S.; van Boom, J. H.; Kessler, H.; Overhand, M. Eur. J. Org. Chem. 2003, 2303–2313. doi:10.1002/ejoc.200300031 58. Charkraborty, T. K.; Srinivasu, P.; Bikshapathy, E.; Nagaraj, R.; Vairamani, M.; Kiran Kumar, S.; Kunwar, A. C. J. Org. Chem. 2003, 68, 6257–6263. doi:10.1021/jo034586u 59. Fleet, G. W. J.; Johnson, S. W.; Jones, J. H. J. Pept. Sci. 2006, 12, 559–561. doi:10.1002/psc.759 60. Ellestad, G. A.; Cosulich, D. B.; Broschard, R. W.; Martin, J. H.; Kuntsmann, M. P.; Morton, G. O.; Lancaster, J. E.; Fulmor, W.; Lovell, F. M. J. Am. Chem. Soc. 1978, 100, 2515–2524. doi:10.1021/ja00476a041 61. Nishiyama, T.; Isobe, M.; Ichikawa, Y. Angew. Chem., Int. Ed. 2005, 44, 4372–4375. doi:10.1002/anie.200500892 62. Ichikawa, Y.; Matsukawa, Y.; Tamura, M.; Ohara, F.; Isobe, M.; Kotsuki, H. Chem.– Asian J. 2006, 1, 717–723. doi:10.1002/asia.200600190 63. Ichikawa, Y.; Matsukawa, Y.; Isobe, M. J. Am. Chem. Soc. 2006, 128, 3934–3938. doi:10.1021/ja056253f 64. Ando, O.; Satake, H.; Itoi, K.; Sato, A.; Nakajima, M.; Takahashi, S.; Haruyama, H.; Ohkuma, Y.; Kinishita, T.; Enokita, R. J. Antibiot. 1991, 44, 1165–1168. 65. Storch de Gracia, I.; Bobo, S.; Martín-Ortega, M. D.; Chiara, J. L. Org. Lett. 1999, 1, 1705–1708. doi:10.1021/ol990904t 66. Chiara, J. L.; Storch de Gracia, I.; García, A.; Batida, A.; Bobo, M.; Martín-Ortega, M. D. ChemBioChem 2005, 6, 186–191. doi:10.1002/cbic.200400231 67. Gibson, R. P.; Gloster, T. M.; Roberts, S.; Warren, R. A. J.; Storch de Gracia, I.; García, A.; Chiara, J. L.; Davies, G. J. Angew. Chem., Int. Ed. 2007, 46, 4115–4119. doi:10.1002/anie.200604825 68. López, O.; Maya, I.; Fuentes, J.; Fernández-Bolaños, J. G. Tetrahedron 2004, 60, 61–72. doi:10.1016/j.tet.2003.10.092 69. Kovács, L.; Osz, E.; Györdeák, Z. Carbohydr. Res. 2002, 337, 1171–1178. doi:10.1016/S0008-6215(02)00108-8 70. Díaz Pérez, V. M.; Ortiz Mellet, C.; Fuentes, J.; García Fernández, J. M. Carbohydr. Res. 2000, 326, 161–175. doi:10.1016/S0008-6215(00)00040-9 71. García-Moreno, M. I.; Benito, J. M.; Ortiz Mellet, C.; García Fernández, J. M. J. Org. Chem. 2001, 66, 7604–7614. doi:10.1021/jo015639f 72. García-Moreno, M. I.; Ortiz Mellet, C.; García Fernández, J. M. Eur. J. Org. Chem. 2004, 1803–1819. doi:10.1002/ejoc.200300731 73. Prosperi, D.; Ronchi, S.; Lay, L.; Rencurosi, A.; Russo, G. Eur. J. Org. Chem. 2004, 395–405. doi:10.1002/ejoc.200300483 74. López, O.; Maza, S.; Maya, I.; Fuentes, J.; Fernández-Bolaños, J. G. Tetrahedron 2005, 61, 9058–9069. doi:10.1016/j.tet.2005.07.041 75. Prosperi, D.; Ronchi, S.; Lay, L.; Rencurosi, A.; Russo, G. Synlett 2004, 1529–1532. doi:10.1055/s-2004-829074 76. Jiménez Blanco, J. L.; Bootello, P.; Benito, J. M.; Ortiz Mellet, C.; García Fernández, J. M. J. Org. Chem. 2006, 71, 5136–5143. doi:10.1021/jo060360q 77. Benito, J. M.; Rodríguez-Lucena, D.; Jiménez Blanco, J. L.; Ortiz Mellet, C.; García Fernández, J. M. J. Inclusion Phenom. Macrocyclic Chem. 2007, 57, 147–150. doi:10.1007/s10847-006-9203-1 78. Rodríguez-Lucena, D.; Benito, J. M.; Álvarez, E.; Jaime, C.; Perez-Miron, J.; García Fernández, J. M. J. Org. Chem. 2008, 73, 2967–2979. doi:10.1021/jo800048s 79. Rodríguez-Lucena, D.; Ortiz Mellet, C.; Jaime, C.; Burusco, K. K.; García Fernández, J. M.; Benito, J. M. J. Org. Chem. 2009, 74, 2997–3008. doi:10.1021/jo802796p 80. Jiménez Blanco, J. L.; Benito, J. M.; Ortiz Mellet, C.; García Fernández, J. M. Org. Lett. 1999, 1, 1217–1220. doi:10.1021/ol990889s 81. Benito, J. M.; Ortiz Mellet, C.; Sadalapure, K.; Lindhorst, T. K.; Defaye, J.; García Fernández, J. M. Carbohydr. Res. 1999, 320, 37–48. doi:10.1016/S0008-6215(99)00141-X 82. Patel, A.; Lindhorst, T. K. J. Org. Chem. 2001, 66, 2674–2680. doi:10.1021/jo005671u 83. Arya, D. P.; Bruice, T. C. Bioorg. Med. Chem. Lett. 2000, 10, 691–693. doi:10.1016/S0960-894X(00)00085-8 84. Challa, H.; Bruice, T. C. Bioorg. Med. Chem. Lett. 2001, 11, 2423–2427. doi:10.1016/S0960-894X(01)00455-3 85. Jiménez Blanco, J. L.; Bootello, P.; Ortiz Mellet, C.; Gutiérrez Gallego, R.; García Fernández, J. M. Chem. Commun. 2004, 92–93. doi:10.1039/b312743p 86. Jiménez Blanco, J. L.; Bootello, P.; Ortiz Mellet, C.; García Fernández, J. M. Eur. J. Org. Chem. 2006, 183–196. doi:10.1002/ejoc.200500472 87. Jiménez Blanco, J. L.; Bootello, P.; Gutiérrez Gallego, R.; Ortiz Mellet, C.; García Fernández, J. M. Synthesis 2007, 2545–2558. doi:10.1055/s-2007-983794 88. Benito, J. M.; Jiménez Blanco, J. L.; Ortiz Mellet, C.; García Fernández, J. M. Angew. Chem., Int. Ed. 2002, 41, 3674–3676. doi:10.1002/1521-3773(20021004)41:19<3674::AID-ANIE3674>3.0.C O;2-F 89. García Fernández, J. M.; Ortiz Mellet, C.; Defaye, J. J. Inclusion Phenom. Macrocyclic Chem. 2006, 56, 149–159. doi:10.1007/s10847-006-9076-3 90. Tóth, G.; Gáti, T.; Pintér, I.; Kovács, J.; Haessner, R. Magn. Reson. Chem. 2001, 39, 283–287. doi:10.1002/mrc.835 91. Barawkar, D.; Bruice, T. C. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 11047–11052. doi:10.1073/pnas.95.19.11047 92. Barawkar, D.; Linkletter, B. A.; Bruice, T. C. Bioorg. Med. Chem. Lett. 1998, 8, 1517–1520. doi:10.1016/S0960-894X(98)00251-0 93. Linkletter, B. A.; Szabo, I. E.; Bruice, T. C. J. Am. Chem. Soc. 1999, 121, 3888–3896. doi:10.1021/ja984212w 94. Linkletter, B. A.; Bruice, T. C. Bioorg. Med. Chem. 2000, 8, 1893–1901. doi:10.1016/S0968-0896(00)00146-2 95. Kojima, N.; Bruice, T. C. Org. Lett. 2000, 2, 81–84. doi:10.1021/ol9912478 96. Kojima, N.; Szabo, I. E.; Bruice, T. C. Tetrahedron 2002, 58, 867–879. doi:10.1016/S0040-4020(01)01185-1 97. Park, M.; Bruice, T. C. Bioorg. Med. Chem. Lett. 2005, 15, 3247–3251. doi:10.1016/j.bmcl.2005.04.073 98. Park, M.; Toporowski, J. W.; Bruice, T. C. Bioorg. Med. Chem. 2006, 14, 1743–1749. doi:10.1016/j.bmc.2005.10.028 99. Park, M.; Canzio, D.; Bruice, T. C. Bioorg. Med. Chem. Lett. 2008, 18, 2377–2384. doi:10.1016/j.bmcl.2008.02.063 100.Linkletter, B. A.; Szabo, I. E.; Bruice, T. C. Nucleic Acids Res. 2001, 29, 2370–2376. doi:10.1093/nar/29.11.2370 101.Szabo, I. E.; Bruice, T. C. Bioorg. Med. Chem. 2004, 12, 4233–4244. doi:10.1016/j.bmc.2004.05.010 Beilstein Journal of Organic Chemistry 2010, 6, No. 20. Page 18 of (page number not for citation purposes) 18 102.Jain, M. L.; Bruice, T. C. Bioorg. Med. Chem. 2006, 14, 7333–7346. doi:10.1016/j.bmc.2006.05.074 103.Challa, H.; Bruice, T. C. Bioorg. Med. Chem. 2004, 12, 1475–1481. doi:10.1016/j.bmc.2003.12.043 104.Reddy, P. M.; Bruice, T. C. Bioorg. Med. Chem. Lett. 2003, 13, 1281–1285. doi:10.1016/S0960-894X(03)00119-7 105.Reddy, P. M.; Bruice, T. C. J. Am. Chem. Soc. 2004, 126, 3736–3747. doi:10.1021/ja031557s 106.Park, M.; Bruice, T. C. Bioorg. Med. Chem. Lett. 2008, 18, 3488–3491. doi:10.1016/j.bmcl.2008.05.030 107.Zhang, X.; Bruice, T. C. Bioorg. Med. Chem. Lett. 2008, 18, 665–669. doi:10.1016/j.bmcl.2007.11.061 License and Terms This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (http://www.beilstein-journals.org/bjoc) The definitive version of this article is the electronic one which can be found at: doi:10.3762/bjoc.6.20